Here are the top 5 Oncology Nursing News® stories for February 2020.
Here are the top 5 Oncology Nursing News® stories for February 2020.
5. Nurses Must Close the Gap in Geriatric Care
Although there already is a shortage of nurses, even fewer are geriatric certified, making these training programs vital to the future of the oncology nursing field. In this piece from our February issue, we take a closer look at how nurses can prepare for “the silver tsunami”.
4. How Can Mindfulness Help Your Patients?
Here, our partners at CancerCare explore how mindfulness can be a powerful tool to reduce stress and improve patients' outlook after being diagnosed with cancer.
3. Immunotherapy Use Growing in Triple-Negative Breast Cancer
Nearly one year following the first checkpoint inhibitor approval in advanced triple-negative breast cancer, additional immunotherapeutic agents are poised to enter the field, according to this report from the San Antonio Breast Cancer Symposium.
2. Compassion Fatigue Leads to Nurse Turnover
This exclusive piece looks at what can happen when oncology nurses experience compassion fatigue, from nurses leaving their place of employment, to decreased quality of patient care and beyond.
1. PARP Inhibitor Becomes Standard of Care in Ovarian Cancer
After the positive results of the phase III PRIMA trial, frontline niraparib is the new standard of care for patients with newly diagnosed, platinum-sensitive advanced ovarian cancer. We go into what this means for health care teams in this story.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
ESR1 Testing Is Crucial in Second-line HR+, HER2- Metastatic Breast Cancer
September 20th 2024During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in particular with the use of elacestrant, in HR-positive, HER2-negative metastatic breast cancer.